Hepatic impairment does not affect the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide immediately after an individual 5 mg dose was evaluated in patients with distinct levels of hepatic impairment (mild, reasonable, serious) in contrast with topics with standard hepatic perform [see Use In Distinct Populations].Losing weight h